UK markets close in 7 hours 46 minutes

argenx SE (ARGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
318.370.00 (0.00%)
At close: 11:44AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close318.37
Open318.37
BidN/A x N/A
AskN/A x N/A
Day's range318.37 - 318.37
52-week range130.00 - 318.37
Volume17
Avg. volume8
Market cap22.179B
Beta (5Y monthly)0.77
PE ratio (TTM)N/A
EPS (TTM)-12.14
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

    July 22, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argen

  • Globe Newswire

    argenx to Host Virtual R&D Day on July 20, 2021

    July 14, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx 2025 vision’ and provide an update of its immunology pipeline. The event will introduce the fifth and sixth indications for the Company’s FcRn antagonist, efgartigimod,

  • Globe Newswire

    argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology

    Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized myasthenia gravis (gMG) Efgartigimod is under U.S. Food and Drug Administration (FDA) review with December 17, 2021 Prescription Drug User Fee Act (PDUFA) target action date Breda, the Netherlands —Jun. 16, 2021— argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAP